Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Apr-24 7:03 PM View:  | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 15-Apr-24 | Sale (Planned) | 1,270 | $19.99 | $25,383.10 | (< 1%) 204.4K to 203.13K | |
| 15-Apr-24 7:03 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Sale (Planned) | 649 | $25.00 | $16,225.00 | (< 1%) 66.76K to 66.11K | |
| 15-Apr-24 7:06 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 14,903 | $2.48 | $36,959.40 | 4% 396.62K to 411.53K | |
| 12-Apr-24 6:23 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 53,400 | $13.21 | $705,266.00 | 239% 22.34K to 75.74K | |
| 15-Apr-24 7:06 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Sale (Planned) | 2,597 | $25.03 | $65,013.80 | (< 1%) 396.62K to 394.03K | |
| 15-Apr-24 7:02 PM View: | Collins Helen Louise Chief Medical Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 20,000 | $25.07 | $501,478.00 | (100%) 20.0K to 0 | |
| 15-Apr-24 7:05 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 47,709 | $25.04 | $1,194,700.00 | (4%) 1.31M to 1.26M | |
| 15-Apr-24 7:06 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 30,000 | $25.04 | $751,332.00 | (3%) 1.15M to 1.12M | |
| 15-Apr-24 7:04 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 14,000 | $24.72 | $346,149.00 | (100%) 14.0K to 0 | |
| 12-Apr-24 6:23 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 53,400 | $23.95 | $1,279,070.00 | (71%) 75.74K to 22.34K | |
| 15-Apr-24 7:05 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 47,709 | $1.12 | $53,434.10 | 4% 1.26M to 1.31M | |
| 15-Apr-24 7:06 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 30,000 | $1.12 | $33,600.00 | 3% 1.12M to 1.15M | |
| 15-Apr-24 7:03 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Private Sale (Planned) | 5,045 | $25.03 | $126,279.00 | (7%) 71.81K to 66.76K | |
| 15-Apr-24 7:04 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 14,000 | $2.48 | $34,720.00 | 100% 0 to 14.0K | |
| 15-Apr-24 7:06 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Planned Option Sale | 14,903 | $25.03 | $373,085.00 | (4%) 411.53K to 396.62K | |
| 15-Apr-24 7:02 PM View: | Collins Helen Louise Chief Medical Officer | Enliven Therapeutics, Inc. (ELVN) | 11-Apr-24 | Option Exercise | 20,000 | $2.48 | $49,600.00 | 100% 0 to 20.0K | |
| 12-Apr-24 6:23 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 10-Apr-24 | Planned Option Sale | 13,600 | $21.01 | $285,744.00 | (38%) 35.94K to 22.34K | |
| 12-Apr-24 6:23 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 10-Apr-24 | Option Exercise | 13,600 | $12.60 | $171,360.00 | 61% 22.34K to 35.94K | |
| 10-Apr-24 8:35 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 08-Apr-24 | Private Sale (Planned) | 4,875 | $18.60 | $90,686.80 | (1%) 401.5K to 396.62K | |
| 08-Apr-24 8:40 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 04-Apr-24 | Option Exercise | 3,485 | $12.60 | $43,911.00 | 16% 22.34K to 25.83K | |
| 08-Apr-24 8:40 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 04-Apr-24 | Planned Option Sale | 3,485 | $19.15 | $66,729.40 | (13%) 25.83K to 22.34K | |
| 03-Apr-24 9:30 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 01-Apr-24 | Planned Option Sale | 12,000 | $18.60 | $223,146.00 | (1%) 1.13M to 1.12M | |
| 03-Apr-24 9:32 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 01-Apr-24 | Option Exercise | 3,237 | $5.73 | $18,533.80 | 14% 22.34K to 25.58K | |
| 03-Apr-24 9:30 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 01-Apr-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | 1% 1.12M to 1.13M | |
| 03-Apr-24 9:32 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 01-Apr-24 | Planned Option Sale | 3,237 | $19.08 | $61,758.40 | (13%) 25.58K to 22.34K | |
| 29-Mar-24 5:59 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Mar-24 | Planned Option Sale | 3,250 | $18.25 | $59,302.40 | (100%) 3.25K to 0 | |
| 29-Mar-24 5:59 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Mar-24 | Option Exercise | 3,250 | $2.48 | $8,060.00 | 100% 0 to 3.25K | |
| 27-Mar-24 5:03 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Mar-24 | Planned Option Sale | 12,000 | $17.56 | $210,661.00 | (< 1%) 1.28M to 1.26M | |
| 27-Mar-24 5:03 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Mar-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | < 1% 1.26M to 1.28M | |
| 22-Mar-24 7:46 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 20-Mar-24 | Option Exercise | 13,278 | $5.52 | $73,294.60 | 59% 22.34K to 35.62K | |
| 22-Mar-24 7:46 PM View: | Ballal Rahul D. Director | Enliven Therapeutics, Inc. (ELVN) | 20-Mar-24 | Planned Option Sale | 13,278 | $19.16 | $254,462.00 | (37%) 35.62K to 22.34K | |
| 21-Mar-24 6:41 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 19-Mar-24 | Private Sale (Planned) | 1,270 | $14.50 | $18,418.70 | (< 1%) 211.36K to 210.09K | |
| 08-Mar-24 7:52 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 06-Mar-24 | Private Sale (Planned) | 4,875 | $15.64 | $76,238.70 | (1%) 406.37K to 401.5K | |
| 04-Mar-24 5:55 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-Feb-24 | Planned Option Sale | 12,000 | $16.42 | $197,006.00 | (1%) 1.13M to 1.12M | |
| 04-Mar-24 5:55 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-Feb-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | 1% 1.12M to 1.13M | |
| 29-Feb-24 5:27 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Feb-24 | Planned Option Sale | 3,250 | $16.97 | $55,162.90 | (100%) 3.25K to 0 | |
| 29-Feb-24 5:27 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 27-Feb-24 | Option Exercise | 3,250 | $2.48 | $8,060.00 | 100% 0 to 3.25K | |
| 28-Feb-24 10:00 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 26-Feb-24 | Planned Option Sale | 12,000 | $16.89 | $202,653.00 | (< 1%) 1.28M to 1.26M | |
| 28-Feb-24 10:00 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 26-Feb-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | < 1% 1.26M to 1.28M | |
| 20-Feb-24 7:41 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 15-Feb-24 | Private Sale (Planned) | 1,270 | $17.42 | $22,117.40 | (< 1%) 212.63K to 211.36K | |
| 16-Feb-24 4:15 PM View: | 5am Partners Vi, LLC 10% Owner | Enliven Therapeutics, Inc. (ELVN) | 14-Feb-24 | Private Sale | 825,000 | $14.90 | $12,292,500.00 | (18%) 4.66M to 3.84M | |
| 08-Feb-24 8:47 PM View: | Patel Anish Chief Operating Officer | Enliven Therapeutics, Inc. (ELVN) | 06-Feb-24 | Private Sale (Planned) | 4,875 | $15.11 | $73,658.30 | (1%) 411.25K to 406.37K | |
| 02-Feb-24 4:29 PM View: | 5am Partners Vi, LLC 10% Owner | Enliven Therapeutics, Inc. (ELVN) | 31-Jan-24 | Private Sale | 500,000 | $15.00 | $7,500,000.00 | (10%) 5.16M to 4.66M | |
| 01-Feb-24 8:10 PM View: | Heyman Richard A. Director | Enliven Therapeutics, Inc. (ELVN) | 30-Jan-24 | Private Sale (Planned) | 1,270 | $16.41 | $20,839.60 | (< 1%) 213.9K to 212.63K | |
| 31-Jan-24 9:22 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-Jan-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | 1% 1.12M to 1.13M | |
| 31-Jan-24 9:20 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 29-Jan-24 | Option Exercise | 3,250 | $2.48 | $8,060.00 | 100% 0 to 3.25K | |
| 31-Jan-24 9:22 PM View: | Lyssikatos Joseph P Chief Scientific Officer Director | Enliven Therapeutics, Inc. (ELVN) | 29-Jan-24 | Planned Option Sale | 12,000 | $15.85 | $190,256.00 | (1%) 1.13M to 1.12M | |
| 31-Jan-24 9:20 PM View: | Hohl Benjamin Chief Financial Officer | Enliven Therapeutics, Inc. (ELVN) | 29-Jan-24 | Planned Option Sale | 3,250 | $15.81 | $51,388.40 | (100%) 3.25K to 0 | |
| 29-Jan-24 8:01 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Jan-24 | Planned Option Sale | 12,000 | $15.69 | $188,230.00 | (< 1%) 1.28M to 1.26M | |
| 29-Jan-24 8:01 PM View: | Kintz Samuel President and CEO Director | Enliven Therapeutics, Inc. (ELVN) | 25-Jan-24 | Option Exercise | 12,000 | $1.12 | $13,440.00 | < 1% 1.26M to 1.28M |
